Understanding TCEAL2: A Potential Drug Target for Neurological Disorders

Target Name: TCEAL2

NCBI ID: G140597

TCEAL2

Understanding TCEAL2: A Potential Drug Target for Neurological Disorders

TCEAL2 (my048) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a potential drug target (or biomarker) for the treatment of these disorders.

TCEAL2 is a transmembrane protein that is expressed in the brain and is involved in the formation of the blood-brain barrier. It is a key regulator of the Integrin 伪6 ( Integrin 伪6, also known as CD109) receptor, which is involved in the development and progression of various neurological disorders.

The study of TCEAL2 and its role in neurological disorders began in the 1990s, when researchers identified the protein in the brain and determined that it was involved in the formation of the blood-brain barrier. Since then, researchers have continued to study the protein and its role in the development and progression of neurological disorders.

One of the key findings that has emerged from these studies is that TCEAL2 is involved in the regulation of the Integrin 伪6 receptor. The Integrin 伪6 receptor is a key regulator of the blood-brain barrier, and is involved in the development and progression of various neurological disorders, including Alzheimer's disease.

Research has also shown that TCEAL2 is involved in the regulation of the production of neurotransmitters, such as dopamine and glutamate, which are involved in the function of the brain. Additionally, TCEAL2 has been shown to play a role in the regulation of the immune system, which is involved in the development and progression of neurological disorders.

Despite these promising findings, more research is needed to fully understand the role of TCEAL2 in the development and progression of neurological disorders. One of the key areas of focus for future research is to determine the underlying molecular mechanisms that are involved in the regulation of TCEAL2 and its role in the development and progression of neurological disorders.

In conclusion, TCEAL2 is a protein that is expressed in the brain and is involved in the development and progression of various neurological disorders. Its role in the regulation of the Integrin 伪6 receptor and the production of neurotransmitters, as well as its involvement in the regulation of the immune system, make it a promising drug target (or biomarker) for the treatment of these disorders. Further research is needed to fully understand the role of TCEAL2 in the development and progression of neurological disorders and to determine the underlying molecular mechanisms that are involved in its regulation.

Protein Name: Transcription Elongation Factor A Like 2

Functions: May be involved in transcriptional regulation

The "TCEAL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCEAL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets